Gryshkova Vitalina, Fleming Alisha, McGhan Portia, De Ron Pierrette, Fleurance Renaud, Valentin Jean-Pierre, Nogueira da Costa Andre
Investigative Toxicology, Non-Clinical Development, UCB Biopharma SPRL, Belgium.
Faculty of Biological Sciences, LS2 9JT, Leeds, UK.
Toxicol Lett. 2018 Apr;286:31-38. doi: 10.1016/j.toxlet.2018.01.013. Epub 2018 Jan 31.
Investigation of genomic changes in cardiotoxicity can provide novel biomarkers and insights into molecular mechanisms of drug-induced cardiac injury (DICI). The main objective of this study was to identify and characterize dysregulated microRNAs (miRNAs) in the heart associated with cardiotoxicity. Wistar rats were dosed once with either isoproterenol (1.5 mg/kg, i.p), allylamine (100 mg/kg, p.o.) or the respective vehicle controls. Heart tissue was collected at 24 h, 48 h and 72 h post-drug administration and used for histopathological assessment, miRNA profiling, immunohistochemical analysis and in situ hybridization. Multiplex analysis of 68 miRNAs in the heart revealed a significant upregulation of several miRNAs (miR-19a-3p, miR-142-3p, miR-155-5p, miR-208b-3p, miR-21-5p) after isoproterenol and one miRNA (miR-21-5p) after allylamine administration. Localization of miR-21-5p was specific to inflammatory cell infiltrates in the heart after both treatments. Immunohistochemical analysis of Stat3, a known miR-21-5p regulator, also confirmed its upregulation in cardiomyocytes and inflammatory cell infiltrates. The toxicity signatures based on miRNA networks, identified in vivo, can potentially be used as mechanistic biomarkers as well as to study cardiotoxicity in vitro in order to develop sensitive tools for early hazard identification and risk assessment.
对心脏毒性基因组变化的研究可为药物性心脏损伤(DICI)的分子机制提供新的生物标志物和见解。本研究的主要目的是鉴定和表征与心脏毒性相关的心脏中失调的微小RNA(miRNA)。将Wistar大鼠一次性给予异丙肾上腺素(1.5mg/kg,腹腔注射)、烯丙胺(100mg/kg,口服)或相应的溶剂对照。在给药后24小时、48小时和72小时收集心脏组织,用于组织病理学评估、miRNA谱分析、免疫组织化学分析和原位杂交。对心脏中68种miRNA的多重分析显示,异丙肾上腺素给药后几种miRNA(miR-19a-3p、miR-142-3p、miR-155-5p、miR-208b-3p、miR-21-5p)显著上调,烯丙胺给药后一种miRNA(miR-21-5p)上调。两种处理后,miR-21-5p的定位均特异性定位于心脏中的炎性细胞浸润。对已知的miR-21-5p调节因子Stat3的免疫组织化学分析也证实其在心肌细胞和炎性细胞浸润中上调。基于体内鉴定的miRNA网络的毒性特征,有可能用作机制生物标志物,也可用于体外研究心脏毒性,以开发早期危害识别和风险评估的敏感工具。